Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis

OBJECTIVE: The novel synergistic drug candidate CRx-102 comprises dipyridamole and low dose prednisolone and is in clinical development for the treatment of immunoinflammatory diseases. The purpose of this clinical study was to examine the efficacy and safety of CRx-102 in patients with hand osteoar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kvien, T K, Fjeld, E, Slatkowsky-Christensen, B, Nichols, M, Zhang, Y, Prøven, A, Mikkelsen, K, Palm, Ø, Borisy, A A, Lessem, J
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Extended Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564788/
https://www.ncbi.nlm.nih.gov/pubmed/17962237
http://dx.doi.org/10.1136/ard.2007.074401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564788/
https://www.ncbi.nlm.nih.gov/pubmed/17962237
http://dx.doi.org/10.1136/ard.2007.074401

Ejemplares similares